



# BEST-CLI: New Data and Evolving Perspectives

---

Thursday, November 16, 2023 | Location: Murray Hill Suites, 2nd Floor | Time: 3:00 P.M. - 5:00 P.M.

Moderators: Alik Farber, MD, MBA, Matthew T. Menard, MD and Kenneth Rosenfield, MD

---

The BEST-CLI trial will be the central focus for two hours on Thursday, November 16<sup>th</sup> from 3-5 P.M. at the VEITHsymposium in New York City. BEST-CLI Principal Investigators Drs. Alik Farber, Matthew Menard and Kenneth Rosenfield will moderate a deep and data-rich dive into recent work, future plans, comments from opinion leaders and a debate on the evolving interpretation of BEST-CLI.

The program will highlight recent analyses and forthcoming publications on Periprocedural Complications, Reinterventions, a number of novel but highly relevant Secondary Endpoints, a comprehensive BEST-CLI Investigator Survey and open and endo comparison of Infrapopliteal Interventions within the trial.

Special Guest Andrew Bradbury, the PI of both BASIL-1 and BASIL-2 and the soon to be released BASIL-3, will take the stage to discuss the emerging results of BASIL-2, centering a robust discussion on how to interpret the conflicting results with BEST-CLI. We will hear the perspectives of a number of the BEST-CLI Executive Committee, including John Kaufman, Michael Dake, Richard Powell and Michael Conte, who were instrumental in the design and conduct of the trial and will share their perspective on how the results should be interpreted.

We will finish with a flourish, with a debate between two worthy combatants, Dr. Ramon Varcoe and Dr. Michael Conte, on "The Meaning of BEST-CLI" and will hear the comments of a number of thoughtful leaders in the field, including Drs. Peter Schneider, Robert Lookstein, Maarit Venermo, Joseph Mills, Elizabeth Genovese, and Carlos Mena. There will be ample time throughout the forum for audience feedback and participation. Please join us. Refreshments will be served.

## INTRODUCTION

5M

BEST-CLI PIs

*Alik Farber, MD, MBA*

*Matthew T. Menard, MD*

*Kenneth Rosenfield, MD*

## RECENT WORK

4M

PeriProcedural Complications/MACE

*Jeffrey J. Siracuse, MD, MBA, FACS*

4 M

Reinterventions

*Michael S. Conte, MD*

4 M

Secondary Outcomes

*Matthew T. Menard, MD*

4 M

Survey of BEST-CLI Investigators

*Alik Farber, MD, MBA*

6 M

BASIL & Follow-Up

*Andrew W. Bradbury, MD, FRCSEd*

5 M

European Propensity Matched Analysis

*Jean-Baptiste Ricco, MD, PhD*

## FUTURE PLANS

3M

BEST-CLI PIs

BEST-CLI Vision & Publication Plans

5M

Q &A

Open Discussion

## COMMENTS FROM OPINION LEADERS

3M

Peter A. Schneider, MD

3M

Robert A. Lookstein, MD

3M

Joseph L. Mills, MD

3M

Elizabeth Genovese, MD

3M

Maarit Venermo, MD, PhD

3M

Carlos Mena, MD

10M

Q&A

## DEBATE: INFRAINGUINAL BYPASS SHOULD ALMOST NEVER BE THE PREFERRED INITIAL APPROACH IN CLTI PATIENTS

8M

Argument

*Ramon L. Varcoe, MBBS, MS, FRACS, PhD*

8M

Argument

*Michael S. Conte, MD*

3M

Rebuttal

*Ramon L. Varcoe, MBBS, MS, FRACS, PhD*

3M

Rebuttal

*Michael S. Conte, MD*

## EXECUTIVE COMMITTEE PANEL

Panel will be at a table up front and will discuss the debate and take questions from the audience for 30 mins

*John A. Kaufman, MD, MS*

*Michael D. Dake, MD*

*Richard J. Powell, MD*

*Michael S. Conte, MD*